Hikma Pharmaceuticals Fair Value
H5
The fair market value of H5P.MU stock is 12.19 EUR. Relative to the market price of 0 EUR Hikma Pharmaceuticals is overvalued by 45.1%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Hikma Pharmaceuticals Valuation
The fair value level of 12.19 EUR can be considered as an effective entry point for long-term investors to start investing in H5P.MU stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Market price:
H5P.MU stock is greatly overvalued
It means the current price may concern as a High Risk Entry Point
Hikma Pharmaceuticals PLC Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
15.55
2
Median P/E over 5 years
9.08
3
Minimum P/E over 5 years
7.45
4
Earning per share (last 12 months)
1.42 USD
Maximum value
1
x
4
=
20.87 EUR
Fair value
2
x
4
=
12.19 EUR
Minimum value
3
x
4
=
10 EUR
Hikma Pharmaceuticals PLC price metrics
-0.58
Annual return (geometric mean)
28.86
Risk (standard deviation) of returns
β
0.64
Beta (volatility compared to market)